Immune therapy eliminates tumor cells in early triple negative breast cancer

Posted · Add Comment
scidaily-logo-rss

Immune therapy added to chemotherapy improves pathological complete response in patients with early triple negative breast cancer, according to new results from the KEYNOTE-522 trial. Interim results from the study, which is the first phase III trial of immunotherapy in early breast cancer, also indicated an improvement in event-free survival.

This full article appears on <a href="https://www.sciencedaily.com/releases/2019/09/190930181017.htm">Science Daily</a>

Leave a Reply

Your email address will not be published. Required fields are marked *